CO₂

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: CO₂
• 英文别名: Ketenhydrat
• 化学式: C₂H₂O*H₂O
• 分子量: 60.0526
• InChiKey: HKDNMKSZNAFAKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.82
• 重原子数：
  4
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  18.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-二甲基胺-2-丙炔 、 CO₂ 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 4-dimethylamino-2-butynoic acid
  参考文献：
  名称：

  Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases

  摘要：

  这项发明提供了具有结构的化合物，可作为蛋白酪氨酸激酶抑制剂。

  公开号：

  US06355636B1
• 作为产物：
  描述：

  1,6-己二胺 生成 CO₂
  参考文献：
  名称：

  BLENDS OF AMINES WITH PIPERAZINE FOR CO2 CAPTURE

  摘要：

  与去除酸性气体相关的组合物和方法。具体来说，本公开涉及一种组合物和方法，用于利用包含吡啶和至少一种二胺或三胺的溶剂从气体混合物中去除酸性气体。

  公开号：

  US20150073150A1
• 作为试剂：
  描述：

  2-氨基苯甲腈 在 CO₂ 作用下， 生成 2,4-喹唑啉二酮
  参考文献：
  名称：

  Synthetic approaches, functionalization and therapeutic potential of quinazoline and quinazolinone skeletons: The advances continue

  摘要：

  The presence of N-heterocycles as an essential structural motif in a variety of biologically active substances has stimulated the development of new strategies and technologies for their synthesis. Among the various N-heterocyclic scaffolds, quinazolines and quinazolinones form a privileged class of compounds with their diverse spectrum of therapeutic potential. The easy generation of complex molecular diversity through broadly applicable, cost-effective, practical and sustainable synthetic methods in a straightforward fashion along with the importance of these motifs in medicinal chemistry, received significant attention from researchers engaged in drug design and heterocyclic methodology development. In this perspective, the current review article is an effort to recapitulate recent developments in the eco-friendly and green procedures for the construction of highly challenging and potentially bioactive quinazoline and quinazolinone compounds in order to help medicinal chemists in designing and synthesizing novel and potent compounds for the treatment of different disorders. The key mechanistic insights for the synthesis of these heterocycles along with potential applications and manipulations of the products have also been conferred. This article also aims to highlight the promising future directions for the easy access to these frameworks in addition to the identification of more potent and specific products for numerous biological targets. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.10.084

文献信息

• Oxazole and isoxazole derivatives having anti-arthritic activity
  申请人：Hoffmann-La Roche Inc.

  公开号：US04774253A1

  公开（公告）日：1988-09-27

  Oxazole and isoxazole derivatives of the formula ##STR1## wherein A is C.sub.1-6 -alkylene, Het is a 2-R-oxazol-5-yl, 5-R-oxazol-2-yl, 4-R-oxazol-2-yl, 2-R-oxazol-4-yl, 3-R-isoxazol-5-yl or 5-R-isoxazol-3-yl group which is optionally substituted on the heterocyclic ring by a C.sub.1-6 -alkyl group, R is phenyl or thienyl monosubstituted or disubstituted by halogen, trifluoromethyl or C.sub.1-6 -alkylthio, R.sup.1 and R.sup.2 each is a C.sub.1-6 -alkyl group and R.sup.3 is a hydroxy or C.sub.1-6 -alkoxy group or a group of the formula --NR.sup.4 R.sup.5 in which R.sup.4 and R.sup.5 each is a hydrogen atom or a C.sub.1-6 -alkyl group or R.sup.4 and R.sup.5 together with the nitrogen atom to which they are attached is a 5-membered or 6-membered saturated heteromonocyclic ring which may contain an oxygen or sulphur atom or an additional nitrogen atom, and pharmaceutically acceptable salts of the compounds of formula I in which R.sup.3 is a hydroxy group with bases, have anti-arthritic activity.

  式为##STR1##的噁唑和异噁唑衍生物，其中A是C.sub.1-6-烷基，Het是2-R-噁唑-5-基，5-R-噁唑-2-基，4-R-噁唑-2-基，2-R-噁唑-4-基，3-R-异噁唑-5-基或5-R-异噁唑-3-基，该基在杂环环上可以选择性地被C.sub.1-6-烷基取代，R是苯基或噻吩基，经卤素，三氟甲基或C.sub.1-6-烷基硫代取代的单取代或双取代，R.sup.1和R.sup.2各自是C.sub.1-6-烷基，R.sup.3是羟基或C.sub.1-6-烷氧基或式--NR.sup.4 R.sup.5的基团，其中R.sup.4和R.sup.5各自是氢原子或C.sub.1-6-烷基，或R.sup.4和R.sup.5与它们所连接的氮原子一起是一个含氧或硫原子或额外的氮原子的5-成员或6-成员饱和杂环单环，以及公认的药物可接受的盐，其中R.sup.3是羟基的化合物和碱有抗关节炎活性。
• THIAZOLOPYRIMIDONES AS INHIBITORS OF DDR1/2 AND THERAPEUTIC USES THEREOF
  申请人：Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO)

  公开号：EP4032896A1

  公开（公告）日：2022-07-27

  The present invention relates to a group of compounds of formula (I): which are inhibitors of the Discoidin Domain Receptors (DDR1/2), whose overexpression is produced in several diseases such as cancer, pulmonary fibrosis, cirrhotic liver, liver fibrosis, lupus nephritis, osteoarthritis, rheumatoid arthritis and atherosclerosis, so the compounds of the invention are useful for the treatment of said diseases.

  本发明涉及一组式（I）的化合物，它们是Discoidin Domain Receptors（DDR1/2）的抑制剂，其过度表达在多种疾病中产生，例如癌症，肺纤维化，肝硬化，肝纤维化，狼疮性肾炎，骨关节炎，类风湿性关节炎和动脉粥样硬化等，因此本发明的化合物对于治疗上述疾病是有用的。
• Poly(alkylene carbonate) monoahls and polyahls useful as surfactants
  申请人：The Dow Chemical Company

  公开号：US04895970A1

  公开（公告）日：1990-01-23

  Poly(alkylene carbonate) monoahls and polyahls useful as non-ionic surfactants having a poly(alkylene carbonate) backbone are prepared by reacting an oligomeric poly(alkylene carbonate) with a compound having mono- or difunctional active hydrogen moieties, such as alcohols, carboxylic acids, mercaptans, amides, primary or secondary amines, or substituted phenols, in the presence of a catalyst under transesterification conditions. Novel modified poly(alkylene carbonate)monoahls and polyahls are prepared by reactions of mercaptans with poly(alkylene carbonate)polyahls.

  聚(烷基碳酸酯)单醇和多醇可用作具有聚(烷基碳酸酯)骨架的非离子表面活性剂，方法是在催化剂存在下，将寡聚聚(烷基碳酸酯)与具有单-或双官能活性氢基团的化合物（如醇，羧酸，巯基，酰胺，一级或二级胺或取代苯酚）在酯交换条件下反应。通过巯基与聚(烷基碳酸酯)多醇反应制备了新型改性聚(烷基碳酸酯)单醇和多醇。
• COPOLYMERS OF PERFLUOROCYCLOALIPHATIC METHYL VINYL ETHER
  申请人：3M INNOVATIVE PROPERTIES COMPANY

  公开号：US20220033673A1

  公开（公告）日：2022-02-03

  Described herein is a perfluoropolymer and compositions therefrom. The perfluoropolymer is derived from: (a) no more than 88 mol % tetrafluoroethylene monomer; and (b) a complementary amount of a perfluoro (cycloaliphatic methyl vinyl ether) monomer, and has substantially no melting point.
• US2015/73188
  申请人：——

  公开号：——

  公开（公告）日：——